阿折地平而非氨氯地平可降低2型糖尿病患者的尿白蛋白排泄及颈动脉粥样硬化：2型糖尿病患者使用奥美沙坦和阿折地平控制血压（BOAT2研究）。
Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study).
作者信息
Tawaramoto Kazuhito, Kaneto Hideaki, Hashiramoto Mitsuru, Kawasaki Fumiko, Tatsumi Fuminori, Shimoda Masashi, Kamei Shinji, Matsuki Michihiro, Mune Tomoatsu, Kaku Kohei
机构信息
Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192 Japan ; Takarazuka Daiichi Hospital, Takarazuka, Japan.
Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, 577 Matsushima, Kurashiki, 701-0192 Japan.
出版信息
Diabetol Metab Syndr. 2015 Sep 17;7:80. doi: 10.1186/s13098-015-0073-9. eCollection 2015.
To evaluate the efficacy of azelnidipine and amlodipine on diabetic nephropathy and atherosclerosis, we designed a prospective and randomized controlled clinical study in type 2 diabetic patients with stable glycemic control with fixed dose of anti-diabetic medication. Although there was no difference in blood pressure between both groups, urinary albumin excretion and maximum carotid intima-media thickness were reduced in azelnidipine group, but not in amlodipine group. In addition, inflammatory cytokine levels were decreased only in azelnidipine group which possibly explains such beneficial effects of azelnidipine on urinary albumin excretion and carotid atherosclerosis.
为评估阿折地平与氨氯地平对糖尿病肾病和动脉粥样硬化的疗效，我们设计了一项前瞻性随机对照临床研究，纳入使用固定剂量抗糖尿病药物且血糖控制稳定的2型糖尿病患者。尽管两组血压无差异，但阿折地平组的尿白蛋白排泄量和颈动脉内膜中层最大厚度降低，而氨氯地平组未降低。此外，仅阿折地平组的炎症细胞因子水平降低，这可能解释了阿折地平对尿白蛋白排泄和颈动脉粥样硬化的有益作用。
Zotero 插件